Healthcare Innovations in Precision Medicine and Biomanufacturing Platforms Updated Research Available

Life Science, Health & Wellness Technology Opportunity Engine

INDUSTRY
Healthcare

RELEASE DATE
16-May-2025
REGION
Global
DELIVERABLE TYPE
Technology Research

RESEARCH CODE
D759-00-4G-00-00
SKU
HC_2025_34061
Yes
SHARE

Innovations in Precision Medicine and Biomanufacturing Platforms
Published on: 16-May-2025 | SKU: HC_2025_34061

Need more details?

$950.00

$855.00 save 10 %

DownloadLink
Need more details?

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across innovations in precision medicine, targeted drug delivery, RNA editing, biomanufacturing, cell and gene therapies. The research also comprises advances in single cell analysis, hybrid microbots, AI-powered diagnostic, bioprinting and non-communicable disease management technologies.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Precision Medicine, Immunomodulation, Inflammatory Diseases, Immunotherapy, Antibody-drug conjugate, targeted drug delivery, cell and gene therapy, CGT manufacturing, RNA editing, AAV, gene therapy, central nervous system (CNS) disorders, circular RNA vaccine, single cell analysis, AI-powered algorithm, coronary artery diseases, plaque morphology, hybrid microbots, high throughput bioprinting, brain scanners, RNAi therapies, GIP Antagonist, Leukemia, hemophilia, T-cell engagers,

Dual-Action CRAC Channel Inhibition for Targeted Tissue Protection and Broad Immune Modulation in Acute and Chronic Inflammatory Diseases

Next-Generation HLA-Based Multi-Target Immunotherapy Platform for Broad Immune Activation

Endosomal Escape-Enhanced Payload Delivery Platform with Targeted Intracellular Accumulation for Improved Therapeutic Efficacy

LimONE: Scalable, Automated, and Closed-Loop Platform for Efficient Cell and Gene Therapy Manufacturing

Axiomer RNA Editing: Versatile, Transient, and Precise Therapeutics Powered by Endogenous Enzymes

Cost-Effective Circular-RNA-Based Vaccines That Offer Stability at Room Temperature

Ultra-high Throughput Single-cell Analysis Based on Semi-Permeable Capsules

AI-powered coronary computed tomography angiography CCTA For Early Detection of Coronary Artery diseases

AI-powered imaging to analyze Plaque morphology

Hybrid Microrobots to Enable Targeted and Precise Delivery At Intended Site

High-Throughput Bioprinting technology to create functional Tissue faster

Cerca OPM-MEG System— World’s Most Advanced Brain Scanner

HCR-188 First-in-Class GIP Antagonist for the Treatment of Obesity

TGRX-678 Treat Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Ph-cml Or CML

BE-101 Treatment of Adults with Moderately Severe or Severe Hemophilia B

UB-VV111 A Lentiviral Vector-based Gene Therapy

NRM-823 T Cell Engager With Tumor-specific Targeting


Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related In Vitro Diagnostics (IVD) research

27 Aug 2026   |   Global   |   Frost Radar

Frost Radar: AI-Powered Molecular Diagnostics, 2026

AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...

25 Aug 2026   |   Global   |   Technology Research

Breakthrough Innovations in Point-of-Care Diagnostics

This research analyzes how point-of-care (PoC) diagnostics is evolving from simple tests to decentralized, connected, and clinically actionable testing platforms across hospitals, outpatient settings, homes, and pharmacies.The study assesses key technology shifts, including rapid molecular testing, ...

21 Aug 2026   |   Global   |   Technology Research

Innovations and Growth Opportunities in AI-Driven Biomanufacturing, Advanced Cell and Gene Therapies, and Precision Immunotherapy

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping biomanufacturing, cell and gene therapy, precision immunotherapy, anti-infectives, and neurotherapeutics across oncology, infectious disease...

07 Aug 2026   |   Global   |   Customer Research

Laboratory Product Purchasing Trends, United States and Europe, 2025–2026

Qualified respondents to this Frost & Sullivan survey were invited to participate in an online survey examining their laboratory’s product purchasing process in 2025 and expectations for 2026. Frost & Sullivan has conducted similar studies among the same target respondent groups since 2012. The surv...

21 Jul 2026   |   Global   |   Market Research

Point-of-Care Testing Market, Global, 2024–2031

The global POCT market is rapidly evolving from standalone rapid diagnostics to connected, AI-enabled clinical intelligence ecosystems that support decentralized healthcare delivery. Growth is driven by the increasing demand for faster clinical decision-making, early disease detection, personalized ...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across innovations in precision medicine, targeted drug delivery, RNA editing, biomanufacturing, cell and gene therapies. The research also comprises advances in single cell analysis, hybrid microbots, AI-powered diagnostic, bioprinting and non-communicable disease management technologies.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Precision Medicine, Immunomodulation, Inflammatory Diseases, Immunotherapy, Antibody-drug conjugate, targeted drug delivery, cell and gene therapy, CGT manufacturing, RNA editing, AAV, gene therapy, central nervous system (CNS) disorders, circular RNA vaccine, single cell analysis, AI-powered algorithm, coronary artery diseases, plaque morphology, hybrid microbots, high throughput bioprinting, brain scanners, RNAi therapies, GIP Antagonist, Leukemia, hemophilia, T-cell engagers,
More Information
Deliverable Type Technology Research
Industries Healthcare
No Index No
Is Prebook No
Podcast No
Predecessor D759-00-4F-00-00
WIP Number D759-00-4G-00-00

Innovations in Precision Medicine and Biomanufacturing Platforms

$950.00

Special Price $855.00 save 10 %

In stock
SKU
HC_2025_34061